Bristol-Myers Squibb has new data backing up the value of mavacamten for obstructive hypertrophic cardiomyopathy (HCM), as it waits for a delayed verdict on its marketing application for the drug ...

Cytokinetics is playing catch-up with mavacamten, another myosin inhibitor which already has phase 3 results in place showing it can improve patients' heart function and oxygen consumption ...

Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early January 2026. These ...